Sander Dale A. 4
4 · Humacyte, Inc. · Filed Dec 12, 2022
Insider Transaction Report
Form 4
Humacyte, Inc.HUMA
Sander Dale A.
CFO and Chief Corp. Deve. Off.
Transactions
- Award
Stock Options (right to buy)
2022-12-08+136,000→ 136,000 totalExercise: $3.07Exp: 2032-12-08→ Common Stock (136,000 underlying)
Footnotes (1)
- [F1]The first 25% of the option becomes exercisable on December 8, 2023, after which 1/48 of the option will become exercisable on the 8th of each month through December 8, 2026.